Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 85

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 85
---
 and the plans and objectives of management for future operations, are forward-looking statements.
Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek”
and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements
relate to future events or future performance, but reflect management’s current beliefs, based on information currently available.
A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed
in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially
from those anticipated in the forward-looking statements, please refer to the “Risk Factors” section of the Company’s
final prospectus for its initial public offering filed with the U.S. Securities and Exchange Commission (the “SEC”). The
Company’s filings with the SEC can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly
required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements
whether as a result of new information, future events or otherwise.

Overview

We
are a blank check company incorporated in the Cayman Islands on May 23, 2024 formed for the purpose of effecting a merger, share exchange,
asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
We intend to effectuate our initial business combination using cash derived from the proceeds of the Initial Public Offering (as defined
below) and the sale of the Private Placement Units (as defined below), our shares, debt or a combination of cash, shares and debt.

We
expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete
an initial business combination will be successful.

While
we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses
in the pharmaceutical industry. The Company is an early stage and emerging growth company and, as such, the Company is subject to all
of the risks associated with early stage and emerging growth companies.

The
registration statement for the Company’s initial public offering (the “IPO” or “Initial Public Offering”)
was declared effective on January 27, 2025. On January 29, 2025, we consummated our Initial Public Offering of 20,000